Zhejiang Jianfeng Group Receives Drug Registration for Sodium Hyaluronate Eye Drops
Zhejiang Jianfeng Group (SHA:600668) received the drug registration certificate of sodium hyaluronate eye drops. The registration is expected to further enrich the company's product line and help enha
Zhejiang Jianfeng Group (600668.SH): Received the pharmaceutical registration certificate for sodium boric acid eye drops.
Jianfeng Group (600668.SH) announced that its wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. (referred to as "Jianfeng Pharmaceutical") and its controlling subsidiary Zhejiang Erying Pharmaceutical Co., Ltd. (referred to as "Erying Company") has received the drug registration certificate for sodium hyaluronate eye drops issued by the National Medical Products Administration.
China Approves Jianfeng's Marketing Application for Antibiotic Raw Material
China approved Zhejiang Jianfeng Group (SHA:600668) subsidiary Zhejiang Jianfeng Pharmaceutical's marketing application for its cefmenoxime hydrochloride raw material, according to a Tuesday filing wi
Jianfeng Group (600668.SH): The active ingredient cefmetoxime hydrochloride was approved for listing
Jianfeng Group (600668.SH) announced that recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the country...
Jianfeng Group (600668.SH): No atropine sulphate products
Gelonghui, May 22丨Jianfeng Group (600668.SH) said on the investor interactive platform that the company has no atropine sulfate products.
Jianfeng Group (600668.SH): Subsidiaries do not produce synthetic biological materials
Gelonghui, May 17丨Jianfeng Group (600668.SH) said on the investor interactive platform that its subsidiary Jianfeng Health produces plant-derived rhodiola extract and does not produce synthetic biological raw materials.
Zhejiang Jianfeng's Pharmaceutical Unit Gets Nod to Market Anti-Tumor Drug
China's National Medical Products Administration approved the application of Zhejiang Jianfeng Group's (SHA:600668) unit, Jianfeng Pharmaceutical, to register raw drug ingredient imatinib mesylate for
Jianfeng Group (600668.SH): Imatinib mesylate obtains approval notice for application for marketing of chemical raw materials
Gelonghui on May 13 丨 Jianfeng Group (600668.SH) announced that Zhejiang Jianfeng Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the “Notice of Approval of the Chemical Ingredient Marketing Application” from the State Drug Administration regarding the chemical ingredient imatinib mesylate. Imatinib mesylate is the mesylate salt of imatinib, a tyrosine kinase inhibitor with antitumor activity.
Jianfeng Group's Pharma Unit Gets Nod to Sell Glaucoma Eye Drops
Zhejiang Jianfeng Pharmaceutical, a unit of cement products manufacturer Zhejiang Jianfeng Group (SHA:600668), obtained approval from China's National Medical Products Administration to produce and ma
Zhejiang Jianfeng Group's (SHSE:600668) Soft Earnings Are Actually Better Than They Appear
Soft earnings didn't appear to concern Zhejiang Jianfeng Group Co., Ltd.'s (SHSE:600668) shareholders over the last week. We did some digging, and we believe the earnings are stronger than they seem.
Jianfeng Group (600668.SH): Net profit of 2,4283 million yuan in the first quarter decreased by 89.51% year-on-year
Gelonghui, April 29丨Jianfeng Group (600668.SH) released its report for the first quarter of 2024, achieving operating income of 602 million yuan, a year-on-year decrease of 0.93%; net profit attributable to shareholders of listed companies was 2,4283 million yuan, a year-on-year decrease of 89.51%; and basic earnings per share were 0.0071 yuan.
Jianfeng Group (600668.SH): The subsidiary received a notice of approval of the drug supplement application
Gelonghui, April 24, Jianfeng Group (600668.SH) announced that Jianfeng Pharmaceutical, a wholly-owned subsidiary of the company, has received the “Drug Supplement Application Approval Notice” (Notice No.: 2024B01710, 2024B01711, 2024B01712) approved and issued by the State Drug Administration.
Jianfeng Group (600668.SH): Injectable cefmetoxime hydrochloride passed generic drug consistency evaluation
Jianfeng Group (600668.SH) issued an announcement, and the company obtained the “Drug Supplement Application...” for injectable cefmetoxime hydrochloride
Jianfeng Group (600668.SH): Employee Supervisor Pang Xiong passed away
Gelonghui, April 17, 丨 Jianfeng Group (600668.SH) announced that Mr. Pang Xiong, employee supervisor of the 11th Supervisory Board, unfortunately passed away on April 16, 2024 due to ineffective medical treatment. During his tenure at the company, Mr. Pang Xiong worked diligently, performed his duties with due diligence, and faithfully carried out the duties and obligations of supervisors. The company expressed its deep condolences on the death of Mr. Pang Xiong and extended its deepest condolences to his family.
There's No Escaping Zhejiang Jianfeng Group Co., Ltd.'s (SHSE:600668) Muted Earnings
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 27x, you may consider Zhejiang Jianfeng Group Co., Ltd. (SHSE:600668) as an attractive investment with its 13
Jianfeng Group (600668.SH): Acetaminophen suppositories obtained drug registration certificate
Gelonghui January 19 丨 Jianfeng Group (600668.SH) announced that Zhejiang Erying Pharmaceutical Co., Ltd., a holding subsidiary of the wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received the “Drug Registration Certificate” for acetaminophen suppositories approved and issued by the State Drug Administration. Acetaminophen suppositories are antipyretic and analgesic drugs. They are classified as chemical class 3. They are used for fever caused by the common cold or influenza in children, and are also used to relieve mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, and neuralgia.
Jianfeng Group (600668.SH): Subsidiary withdraws drug registration application
Gelonghui January 4 丨 Jianfeng Group (600668.SH) announced that the holding subsidiary Zhejiang Erying Pharmaceutical Co., Ltd. received the “Notice of Termination of Drug Registration Application” from the State Drug Administration regarding Erying's voluntary withdrawal of the registration application for acetaminophen suppositories (specification: 75mg).
Jianfeng Group (600668.SH): The phase I clinical trial of JFAN-1001 capsule has achieved the expected goals, and phase II clinical trial work will begin soon
Gelonghui November 30丨Jianfeng Group (600668.SH) announced that Zhejiang Jianfeng Yien Biotechnology Co., Ltd., a holding subsidiary, has received a summary report on the phase I clinical trial of a new drug, JFAN1001 capsule. The JFAN-1001 capsule phase I clinical study climbing test assessed the tolerability, safety, and pharmacokinetic characteristics of subjects after oral administration of the study drug. The study data showed that JFAN-1001 capsules had good safety and tolerability, and the risk was manageable. The phase I clinical trial of JFAN-1001 capsule achieved the intended goals and proposed for the development of the phase II clinical trial
Zhejiang Jianfeng Unit's Gastroesophageal Reflux Drug Chosen for China's Centralized Procurement
China's Joint Procurement Office selected the esomeprazole magnesium enteric-coated dry suspension of Zhejiang Erying Pharmaceutical, a unit of Zhejiang Jianfeng Group (SHA:600668), to be part of the
Jianfeng Group (600668.SH): “esomeprazole magnesium enteric dry suspension” to win the bid for national drug collection
Jianfeng Group (600668.SH) announced that on November 6, 2023, Zhejiang Jianfeng Pharmaceutical, a holding subsidiary of the company...
No Data